MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
Qing Yuan Zhang(Harbin Medical University), Xi Hu(Sichuan University), Ru Han(Lilly (China)), Roberto Hegg, Zhong Sheng Tong(Breast Cancer Care), Min Yan(Zhengzhou University), Ying Cheng(Jilin Province Tumor Hospital), Tao Sun(Wuhan University), Xin Hong Wu(Hubei Cancer Hospital), Xi Chen(Zhejiang Cancer Hospital), Ning Liao(Guangdong General Hospital), Yi Lu(Shandong Provincial Hospital), Qu Chang Ouyang(Hunan Cancer Hospital), Hai Dong(Lilly (China)), Rômulo Leopoldo de Paula Costa(Instituto do Câncer do Estado de São Paulo), Yong Yin(NewYork–Presbyterian Brooklyn Methodist Hospital), Man Li(Dalian Medical University), Yun Peng Liu(China Medical University), Xiao Jia Wang(Zhejiang Cancer Hospital), Christina Oppermann(Hospital Mãe de Deus), Govind Babu Kanakasetty(Kidwai Memorial Institute of Oncology), M.A. Coccia-Portugal(Right to Care), Z. Jiang(Chinese PLA General Hospital), J. Feng(Hangzhou First People's Hospital), Hui Ping Li(Peking University)
Cited by 110
Related Papers
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k